Weekly FDA Roundup: Supplement Adulteration, CGMP Cluster, and Nicotine Pouch Crackdown — Week of January 3–10, 2026
FDA opened 2026 with a targeted enforcement week: a dietary supplement recalled for undeclared meloxicam, three CGMP warning letters to OTC manufacturers on the same day, and two tobacco retailers cited for unauthorized nicotine pouches.
The first full enforcement week of 2026 arrived with a familiar pattern: FDA opened the year by targeting supplement adulteration, issuing a cluster of CGMP warning letters to OTC drug manufacturers, and continuing its campaign against unauthorized tobacco product retailers. Across 15 regulatory actions published January 3–10, the agency delivered 5 warning letters, 3 recalls, 2 safety alerts, and 5 Federal Register notices — a lean but targeted week with real stakes for supplement brands, contract OTC manufacturers, and tobacco retailers.
By the Numbers
| Action Type | Count |
|---|---|
| Warning Letters | 5 |
| Recalls / Safety Alerts | 5 |
| Federal Register Notices | 5 |
| Total items | 15 |
Lead Story: Silintan Capsules Recalled for Hidden Prescription Drug
The week's most serious consumer safety action was the nationwide voluntary recall of Silintan capsules by Anthony Trinh / 123Herbals LLC, triggered by FDA laboratory analysis finding undeclared meloxicam in a product marketed for "joint and body aches."
Meloxicam is an FDA-approved prescription NSAID (nonsteroidal anti-inflammatory drug) — the kind of drug that carries a black-box warning for elevated risk of cardiovascular thrombotic events (blood clots, heart attack, stroke), gastrointestinal bleeding, ulceration, and perforation. Doses exceeding approved maximums compound these risks significantly, and patients already on prescription meloxicam or other NSAIDs could unknowingly double their exposure.
This isn't a new playbook. It's the exact same scheme the agency has documented in dozens of supplement enforcement actions over the past two years: take a complaint-ready supplement category (joint pain, sexual performance, weight loss), add an undisclosed prescription-class drug to make the product "work," and market it as a natural dietary supplement. The 123Herbals recall fits this template down to the detail — a product sold online under a seemingly herbal brand name, containing a controlled pharmaceutical ingredient that consumers had no way of knowing was there.
Under the Federal Food, Drug, and Cosmetic Act, a supplement containing an undeclared drug is an unapproved new drug, not a dietary supplement. No adverse events had been reported to the company at the time of the recall announcement, but given the cardiovascular and GI risks of unintended NSAID exposure, the absence of reported injuries should be understood as incomplete data, not safety clearance.
Who should care: Supplement brands that contract out manufacturing, retailers who carry third-party herbal supplement lines, and e-commerce platforms with dietary supplement storefronts. If you don't have a testing protocol to verify what's actually in your products, this week's recall illustrates exactly what that gap looks like from the outside.
Key Developments
Three CGMP Warning Letters Hit OTC Drug Manufacturers on the Same Day
On January 6, FDA issued CGMP warning letters to three OTC drug manufacturers simultaneously — a same-day cluster that signals coordinated enforcement, not coincidence.
Absolutely Natural (response deadline: January 21, 2026) drew citations under 21 CFR Parts 210 and 211 for failing to investigate Pseudomonas aeruginosa contamination, failing to validate test methods for Burkholderia cepacia complex (BCC), and — critically — not conducting required identity testing on high-risk raw materials for diethylene glycol (DEG) and ethylene glycol (EG) contamination. DEG contamination in pharmaceutical ingredients has caused mass poisoning events internationally and is a recurring concern in unverified supply chains.
LiquidCapsule Manufacturing, LLC (Tampa, FL; response deadline: January 13, 2026) failed to test incoming raw materials, lacked adequate laboratory controls, had no stability program for shelf-life support, and did not validate its water system — specifically failing to monitor for BCC. Water system validation failures are high-frequency findings in CDER CGMP inspections; here, the concern is direct: BCC can colonize water systems and contaminate finished drug products.
Tower Laboratories Ltd. was cited for failing to thoroughly investigate out-of-specification (OOS) laboratory results and failing to establish scientifically sound test procedures — foundational CGMP failures under 21 CFR 211.192 and 211.160(b).
Three CGMP letters in one day targeting OTC manufacturers who share a common profile — finished drug products, documented water or contamination control failures, inadequate investigations — is a pattern worth noting. It reflects FDA's sustained pressure on the contract manufacturing sector, particularly firms that produce private-label or small-brand OTC products outside the scrutiny applied to major pharmaceutical companies.
FDA Targets Two Tobacco Retailers Selling Unauthorized Nicotine Pouches
The Center for Tobacco Products issued warning letters to bongsociety.com and snuzyn.com for selling ON! Plus nicotine pouches without a premarket marketing authorization order — making the products "new tobacco products" that are adulterated and misbranded under the FD&C Act (21 U.S.C. § 387j).
Both retailers were given 15 working days to respond with corrective action. The ON! Plus products in question are a line extension of the ON! pouch brand, which has FDA marketing authorization for some products but not all formulations. Retailers who assume that brand recognition equals regulatory clearance across an entire product line face exactly this exposure. An authorized brand does not automatically cover new variants, strengths, or delivery formats.
AVID Medical Organ Recovery Kit Correction
AVID Medical issued a correction for its Organ Recovery OR Packs and Medical Convenience Kits after discovering included 24×30 poly bags were not medical-grade and unsuitable for organ transport. The agency's concern is direct: non-medical-grade polymer bags can leach toxic substances and fail sterility standards — in a device designed to maintain the viability of organs destined for transplant, this is a patient safety issue with potentially irreversible consequences.
Affected customers were directed to discard the poly bags and affix warning labels to kits. This correction underscores a procurement control gap that medical device manufacturers share with pharmaceutical companies: assuming that materials sourced as "similar" meet regulatory specifications without verified qualification.
Bendon Candy Recall: Unapproved Color Additive in Children's Licensed Candy
Bendon Publishing recalled multiple lines of heart-shaped gummy candies — sold under licensed children's brands including Paw Patrol, Mickey Mouse, Stitch, SpongeBob Squarepants, and Toy Story — due to the presence of chlorophyllin copper complex, an unapproved color additive under U.S. food regulations. The recall was classified Class III, indicating FDA's assessment that use or exposure is unlikely to cause adverse health consequences, but the products were nonetheless violative. Products distributed broadly through retail channels and likely timed for Valentine's season.
The Bigger Picture
The CGMP warning letter cluster this week fits a longer enforcement arc. Over the past 90 days in the Policy Canary dataset, CGMP violations account for 135 of 711 FDA regulatory actions — nearly one in five. Among the top enforcement categories, prescription and OTC drug manufacturing rank first and second by volume, reflecting FDA's sustained focus on manufacturing quality over product-level approvals.
The supplement adulteration theme (Silintan/meloxicam) is equally persistent. Meloxicam, semaglutide, and other prescription drugs continue to appear as adulterants in products marketed as dietary supplements, energy products, or herbal remedies. The 90-day analytics show semaglutide as the 4th most-cited substance across all FDA actions — a number driven partly by GLP-1 enforcement actions but also by supplement adulteration cases where compounded or diverted semaglutide appears in non-compliant products.
For food manufacturers, the Bendon case is a reminder that licensed co-branding deals don't transfer regulatory compliance responsibility. The manufacturer of the candy bears the violation, but the brand holder — in this case a children's publishing company — faces distribution and reputational exposure from a product recall tied to its IP.
What to Watch
- LiquidCapsule Manufacturing deadline: January 13 — One of the fastest response deadlines in the CGMP cluster. If the firm does not respond with adequate corrective actions, expect escalation.
- Absolutely Natural deadline: January 21 — DEG/EG testing failure is a high-scrutiny issue; inadequate response could trigger import alert or injunction.
- Tobacco product premarket pipeline — ON! Plus retailer letters signal CTP is active on unauthorized line extensions. Retailers carrying new pouch products or flavors from authorized brands should verify PMTAs independently.
- Patent extension notices for ZURZUVAE, IZERVAY, BRENZAVVY, MEDIBEACON, and AUGTYRO were published this week — routine administrative actions with no immediate compliance implications, but relevant for patent strategy teams in pharmaceutical and device companies.
Policy Canary monitors FDA changes for your specific products — by name, by ingredient, by CFR citation. Join the pilot program.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
